Plinabulin Improves Survival and Duration of Response in Advanced Non_Small Cell Lung Cancer

Best Practices in Immunotherapy – June/July 2017 Vol 8

When added to treatment with docetaxel, the investigational drug plinabulin improved overall survival by 4.7 months in patients with advanced non–small cell lung cancer (NSCLC) with measurable lesions. Data from the phase 2 randomized trial also demonstrated durable responses, with median duration of response exceeding 1 year versus less than 2 months with docetaxel alone.

“We saw very encouraging activity for plinabulin in patients with measurable lung disease,” said Alain C. Mita, MD, of Cedars-Sinai Medical Center, Los Angeles, CA. “In addition to durable responses, there was an extended survival benefit of approximately 5 months in these patients.”

As Dr Mita reported at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium, plinabulin is a small molecule with tumor-inhibiting and immune-enhancing effects. For this phase 2 trial, investigators enrolled 163 patients with stage IIIB/IV NSCLC who had received 1 or 2 prior treatments. Patients were randomly assigned to treatment with plinabulin plus docetaxel or docetaxel alone. Docetaxel was dosed at 75 mg/m2 across all arms on day 1 of a 21-day cycle, and plinabulin (20 or 30 mg/m2) was administered on days 1 and 8.

Although the combination of plinabulin plus docetaxel yielded only a modest benefit in the overall study population, in the subset of patients with measurable lesions, median duration of response improved from 1.5 months with docetaxel alone to 12.7 months with the addition of plinabulin. Furthermore, among the 76 patients with measurable disease, median overall survival increased to 11.3 months, compared with 6.7 months with docetaxel alone. Due to the small population size, the 4.6-month improvement in overall survival did not meet statistical significance (P = .26), but the nearly 1-year improvement in duration of response was statistically significant (P <.05), Dr Mita reported.

The addition of plinabulin appeared to exacerbate diarrhea, nausea, vomiting, headache, dizziness, and hypertension; however, the vast majority of these adverse events were “mild, transient, and responded to dose reduction to 20 mg/m2,” said Dr Mita.

Based on these findings, the global phase 3 DUBLIN-3 trial is underway to evaluate second- or third-line treatment with plinabulin and docetaxel in patients with at least 1 measurable lung lesion. At the same time, other NSCLC trials are examining plinabulin’s “potent immune-enhancing effects.” According to Dr Mita, preclinical research in colon and breast tumor models has suggested that plinabulin works in synergy with other immunotherapies to slow tumor growth by operating through mechanisms distinct from PD-1/PD-L1 inhibition. Two investigator-initiated phase 1/2 trials of plinabulin and nivolumab in combination will explore this interaction.

Discussant Heather L. McArthur, MD, MPH, Medical Director of Breast Oncology at Cedars-Sinai Medical Center, called the dramatic increase in overall survival and duration of response “provocative.” Nevertheless, said Dr McArthur, given plinabulin’s complicated mechanism of action, investigators still have “a lot to learn about this drug.”

“It will be important to tease apart the influence of bona fide antitumor effects of the agent from its neutrophil-protecting effects, as the latter may not be of much help when plinabulin is combined with noncytotoxic immunotherapies,” Dr McArthur observed.

Related Articles
Sotorasib Conveys Long-Term Benefits in Patients With KRAS G12C–Mutated Non–Small Cell Lung Cancer
Web Exclusives
Analysis of the long-term results of the CodeBreak 100 clinical trial showed that sotorasib demonstrated long-term efficacy, in particular among patients with low initial circulating tumor DNA values.
NGS Testing More Cost-Effective Than SGT in Oncology
Web Exclusives
A recent study showed that next-generation sequencing testing has superior cost benefit when compared with single-gene testing for multiple cancer types, including non–small cell lung cancer.
Phase 3 Study of Sotorasib in NSCLC Demonstrated Shorter PFS Than Phase 1/2 Trials
Web Exclusives
Analysis of the phase 3 study of sotorasib in patients with non–small cell lung cancer found faster time to response compared with docetaxel but a shorter progression-free survival than what was seen in the phase 1/2 trials.
Last modified: August 10, 2023

Subscribe Today!

To sign up for our print publication or e-newsletter, please enter your contact information below.

I'd like to receive:

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country